Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)
Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T cell engagement and targeting malignant B cells effectively.
Video content above is prompted by the following:
Provide a brief overview of the use of bispecifics antibiotics (BsAbs) in NHL
- Please give a brief overview of the four bispecific antibodies cuused in NHL
- Mosunetuzumab
- Epicortamab
- Glofitamab
Related Content
